Key Inclusion Criteria:

          -  Age ≥ 18 years at time of signing Informed Consent Form

          -  Life expectancy of at least 12 weeks

          -  ECOG Performance Status of 0 or 1

          -  Patients who are either refractory to or intolerant of existing standard therapy or
             for whom no effective further standard of care therapy exists.

          -  No more than three prior therapeutic regimens ("therapeutic" is defined as any
             cytotoxic, biologic, or targeted therapy [approved or investigational] with intent to
             treat the cancer) administered for the treatment of cancer in the advanced/metastatic
             setting.

          -  For dose escalation cohorts only: Patients with either measurable or evaluable
             disease.

          -  Patients with histologic documentation of incurable, locally advanced or metastatic
             prostate cancer with non-measurable disease are eligible if they have an increase in
             prostate-specific antigen (PSA) level of > 50% from current level, the absolute
             increase is ≥ 5 ng/mL, and the increase is confirmed a second time.

          -  Patients with histologic documentation of incurable, locally advanced or metastatic
             ovarian cancer with non-measurable disease are eligible if they have an increase of >
             2 × the baseline level in CA-125 (or > 2 × the ULN in case of prior normal CA-125
             level) and the increase is confirmed a second time.

          -  Adequate organ function as evidenced by (hematologic parameters must be assessed at
             least 14 days from the last growth factor support or prior transfusion, if any):

               -  ANC ≥ 1000/μL.

               -  Total hemoglobin ≥ 9 g/dL.

               -  Platelet count ≥ 100,000/μL.

               -  Serum creatinine ≤ 1.5 × upper limit of normal (ULN), or estimated creatinine
                  clearance ≥ 50 mL/min (Cockcroft Gault or other institutional methods).

               -  Serum aspartate transaminase (AST) and serum ALT ≤ 2 × ULN.

                    -  AST and ALT ≤ 3 × ULN is allowed if liver function abnormalities are due to
                       underlying malignancy.

               -  Total serum bilirubin ≤ 1.5 × ULN regardless of liver involvement secondary to
                  tumor.

                    -  Inclusion of patients with increased serum indirect bilirubin (≤ 3 × ULN)
                       due to Gilbert's syndrome is permitted.

               -  Alkaline phosphatase ≤ 2.5 × the ULN

               -  Albumin ≥3.0 g/dL.

               -  No clinically significant pleural or peritoneal effusion requiring drainage.

        Key Exclusion Criteria:

          -  Prior DR5 agonist therapy.

          -  Prior Bcl-family inhibitor therapy

          -  Concomitant use of agents well-known to cause liver toxicity.

          -  Known clinically significant history of liver disease including Child-Pugh Class B or
             C, including active viral or other hepatitis (e.g., hepatitis B or hepatitis C virus),
             current alcohol abuse, non-alcoholic steatohepatitis (NASH), or cirrhosis.

          -  Diagnosis of any secondary malignancy within 3 years prior to enrollment

          -  Untreated or active central nervous system (CNS) metastases (progressing or requiring
             anticonvulsants or corticosteroids for symptomatic control).

          -  Current Grade > 1 toxicity (except alopecia and anorexia) from prior therapy. Patients
             with current Grade 2 chronic toxicities that are well-controlled by medications may be
             enrolled after discussion with medical monitor.